ID   Hep-G2/C3A-hARG1/hOTC
AC   CVCL_YN89
SY   C3_AO
DR   cancercelllines; CVCL_YN89
DR   Wikidata; Q94102462
RX   DOI=10.1016/j.bbe.2019.12.006;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: HGNC; 663; ARG1.
CC   Transfected with: HGNC; 8512; OTC.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1098 ! Hep-G2/C3A
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 05-10-23; Version: 8
//
RX   DOI=10.1016/j.bbe.2019.12.006;
RA   Pluta K.D., Samluk A., Wencel A., Zakrzewska K.E., Gora M.,
RA   Burzynska B., Ciezkowska M., Motyl J., Pijanowska D.G.;
RT   "Genetically modified C3A cells with restored urea cycle for improved
RT   bioartificial liver.";
RL   Biocybern. Biomed. Eng. 40:378-387(2020).
//